このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

心血管磁気共鳴 (CMR) イメージングの技術的およびトランスレーショナルな開発

心臓血管 MRI (CMR) の技術的およびトランスレーショナルな開発

Background:

Magnetic resonance imaging (MRI) is an important non-invasive tool to study and diagnose cardiovascular disease. MRI scanners use strong magnetic fields and radio waves to create pictures of body organs. Researchers want to find better MRI methods and new ways of imaging cardiovascular disease and better understand normal and abnormal cardiovascular and brain function. Researchers are also interested in seeing if gadolinium, the commonly used MRI contrast agent, stays in the body long after the MRI was performed.

Objectives:

To develop new methods for imaging the heart and other organs of the body.

To describe cardiovascular diseases using newer MRI methods

To look at the relationship between cardiovascular disease and cardiovascular risk factors and other organ systems

To look for gadolinium deposits in the brain from prior exams.

Eligibility:

Healthy people and people with known or suspected cardiovascular disease ages 7 and older may be eligible for this study.

Researchers may be particularly interested in those who:

  • Have suspected or known cardiovascular disease
  • Were previously exposed to a gadolinium-based contrast agent,
  • Need to have a heart MRI scheduled
  • Need a test of the heart or other body part or will be undergoing a future cardiac catheterization

Design:

There are multiple arms to the study with optional components; therefore, there are multiple variations as to what an individual participant s experience may involve.

Participants will have an MRI scan lasting up to 2 hours. The scanner is a large hollow tube. During the scan, there may be loud knocking and buzzing sounds caused by the scanner. Participants will lie on a table that slides in and out of the tube. Their vital signs may be monitored.

Participants may have a test of heart electrical activity using wires connected to pads on the skin.

Participants may have blood drawn.

Participants may be injected with an MRI contrast agent through a plastic tube inserted in the arm.

調査の概要

詳細な説明

The purpose of this protocol is to develop and test new MRI techniques applicable to patients undergoing cardiovascular evaluation with the ultimate goal of translating the technical advances into improving clinical diagnosis and management of patients undergoing cardiovascular evaluation. Patients undergoing cardiovascular evaluation and healthy volunteers will be scanned under the protocol. We will evaluate new developments in non-contrast and contrast MRI of the heart and blood vessels and novel postprocessing methods.

The use of the newer sequences will be used to improve clinical imaging workflow and disease diagnosis. We hope to use this protocol to clearly describe cardiovascular disease and associated problems using novel MRI methods and follow certain subsets of patients with disease as part of a natural history process. Inter-related physiologic systems may be phenotyped by MRI with characterization of disease associations between different organ systems.

Additionally, information regarding gadolinium deposition of the brain will be gathered. The literature regarding deposition of gadolinium in the brain has a large void regarding information of prevalence of the phenomenon in healthy subjects. The National Institutes of Health has a large healthy subject pool who have participated in gadolinium contrast MRI studies. This pool of healthy subjects is not easily available at most clinical MRI centers, and thus, we are uniquely well-situated to be able to answer this outstanding question.

For all objectives, MRI studies will be conducted in the NIH MRI systems located at the NIH Clinical Center in Bethesda, Maryland. These procedures may involve the intravenous administration of commercially available MR contrast media and exercise or pharmacologic stress testing. Results will be used to evaluate the performance of various research pulse sequences, gradient coils, and radiofrequency receiver coils on human subjects and will provide essential ground work for specific patient protocols, both diagnostic and therapeutic.

研究の種類

観察的

入学 (推定)

5000

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

  • 名前:W. Patricia Bandettini, M.D.
  • 電話番号:(301) 451-3128
  • メール:ingkanisorn@nih.gov

研究場所

    • Maryland
      • Bethesda、Maryland、アメリカ、20892
        • 募集
        • National Institutes of Health Clinical Center
        • コンタクト:
          • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
          • 電話番号:TTY8664111010 800-411-1222
          • メール:prpl@cc.nih.gov

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

7年~100年 (子、大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Primary care clinic

説明

  • INCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:
  • Age >= 7 years
  • Able to follow instructions and lie still in the MRI scanner
  • Currently without known Cardiovascular disease
  • Able to provide informed consent in writing or provide guardian consent
  • Willingness to cooperate with all study procedures and available for scheduled study events

EXCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:

  • Important past or chronic medical illness such as major cardiovascular conditions like myocardial infarction, congenital heart disease, and known cardiomyopathy

  • Conditions that are thought to make MRI unsafe (that will be determined by filling out a separate form) including:

    • Cardiac pacemaker or implantable defibrillator unless it is labeled safe or conditional for MRI
    • Cerebral aneurysm clip unless it is labeled safe for MRI
    • Neural stimulator (e.g. TENS-Unit) unless it is labeled safe for MRI
    • Any type of ear or cochlear implant unless it is labeled safe for MRI
    • Ocular foreign body (e.g. metal shavings)
    • Metal shrapnel or bullet unless cleared by plain x-ray as safe for MRI
    • Any implanted device (e.g. insulin pump, drug infusion device), unless it is labeled safe or conditional for MRI
  • eGFR < 60 mL/min/1.73m^2 using the 2021 CKD-EPI equation or equivalent (using the CRIScalculated eGFR to define the threshold) and a serum creatinine measured within 2 weeks without intercurrent change in medical condition or medications. Subjects meeting this exclusion criterion may still be included in the study but may not be exposed to gadolinium-based contrast agents

  • Pregnancy. When uncertain of pregnancy status, subjects will undergo serum or urine pregnancy testing within the 7 days prior to the examination. Among those subjects who will receive MRI contrast, subjects of child-bearing potential will under serum or urine pregnancy testing within 7 days of the day prior to examination. In addition, the subject will be asked if she may be pregnant prior to the performance of the MRI, even if the pregnancy test was negative within the past week. The pregnancy test will be repeated if she answers in the affirmative. Post-menopausal and surgically sterilized subjects are automatically exempt from this testing.

  • If receiving contrast, breast feeding women (unless subject is willing to discard breast milk for 24 hours) are excluded

  • Healthy volunteer children will not have contrast

  • In a year's time, healthy volunteers are not restricted as to the number of non-contrast MRI examinations they undergo, but they may not undergo more than two examinations involving gadolinium-based contrast agents (GBCA) and those exposures will be at least 18 hours (12 half-lives) apart.

INCLUSION CRITERIA FOR SUBJECTS WITH KNOWN OR SUSPECTED WITH HEART DISEASE:

  • Age >= 7 years
  • Subjects with known or suspected cardiovascular disease
  • Able to provide informed consent in writing or provide guardian consent
  • Willingness to cooperate with all study procedures (including food restriction) and available for scheduled study events

EXCLUSION CRITERIA FOR SUBJECTS WITH KNOWN OR SUSPECTED HEART DISEASE:

  • Conditions that are thought to make MRI unsafe (that will be determined by filling out a separate form) including:

    • Cardiac pacemaker or implantable defibrillator unless it is labeled safe or conditional for MRI
    • Cerebral aneurysm clip unless it is labeled safe for MRI
    • Neural stimulator (e.g. TENS-Unit) unless it is labeled safe for MRI
    • Any type of ear or cochlear implant unless it is labeled safe for MRI
    • Ocular foreign body (e.g. metal shavings)
    • Metal shrapnel or bullet unless cleared by plain x-ray as safe for MRI
    • Any implanted device (e.g. insulin pump, drug infusion device), unless it is labeled safe or conditional for MRI
  • Pregnancy. When uncertain of pregnancy status, subjects will undergo serum or urine pregnancy testing within the 7 days prior to the examination. Among those subjects who will receive MRI contrast, subjects of child-bearing potential will undergo serum or urine pregnancy testing 7 days prior to examination. In addition, the subject will be asked if she may be pregnant prior to the performance of the MRI, even if the pregnancy test was negative within the past week. The pregnancy test will be repeated if she answers in the affirmative. Post-menopausal and surgically sterilized subjects are automatically exempt from this testing.

  • Breast feeding (unless subject is willing to discard breast milk for 24 hours if receiving contrast)

  • eGFR < 30 mL/min/1.73m^2 using the 2021 CKD-EPI equation or Community Practice Standard for Pediatric case or equivalent and a serum creatinine measured within 2 weeks without intercurrent change in medical condition or medications. Subjects meeting this exclusion criterion may still be included in the study but may not be exposed to gadolinium-based contrast agents

  • Cardiorespiratory instability as determined by the enrolling clinician

INCLUSION CRITERIA FOR SUBJECTS WITH NON-CARDIAC DISEASE:

  • Age >= 7 years
  • Able to provide informed consent in writing or provide guardian consent
  • Willingness to cooperate with all study procedures (including food restriction) and available for scheduled study events
  • Known or suspected brain, hematology, oncology, endocrine, pulmonary, or other non-cardiac disease.

EXCLUSION CRITERIA FOR SUBJECTS WITH NON- CARDIAC DISEASE:

  • Conditions that are thought to make MRI unsafe (that will be determined by filling out a separate screening form) including:

    • Cardiac pacemaker or implantable defibrillator unless it is labeled safe or conditional for MRI
    • Cerebral aneurysm clip unless it is labeled safe for MRI
    • Neural stimulator (e.g. TENS-Unit) unless it is labeled safe for MRI
    • Any type of ear or cochlear implant unless it is labeled safe for MRI
    • Ocular foreign body (e.g. metal shavings)
    • Metal shrapnel or bullet unless cleared by plain x-ray as safe for MRI
    • Any implanted device (e.g. insulin pump, drug infusion device), unless it is labeled safe or conditional for MRI
  • Pregnancy. When uncertain of pregnancy status, subjects will undergo serum or urine pregnancy testing within the 7 days prior to the examination. Among those subjects who will receive MRI contrast, subjects of child-bearing potential will undergo serum or urine pregnancy testing on the day of the examination. In addition, the subject will be asked if she may be pregnant prior to the

performance of the MRI, even if the pregnancy test was negative within the past week. The pregnancy test will be repeated if she answers in the affirmative. Post-menopausal and surgically sterilized subjects are automatically exempt from this testing.

  • Breast feeding in those subjects receiving contrast (unless subject is willing to discard breast milk for 24 hours
  • eGFR < 30 mL/min/1.73m^2 using the 2021 CKD-EPI equation or equivalent and a serum creatinine measured within 2 weeks without intercurrent change in medical condition or medications. Subjects meeting this exclusion criterion may still be included in the study but may not be exposed to gadolinium-based contrast agents
  • Cardiorespiratory instability or as determined by the enrolling clinician

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
Assessing Gadolinium deposition within the brain in healthy and patient subjects

Both healthy subjects and patient subjects who have previously undergone MRI and received gadolinium.

Child Patient or Healthy Child

Healthy children will be used as controls for children with cardiac disease. Child patient will undergo MRI scans.

Healthy Volunteers

Subjects may be used to test image quality or functionality of MRI sequences; subjects may also be used as controls for adults with cardiac and non-cardiac disease.

Research Patients Cardiac and Non Cardiac

Adults with risk factors for cardiac disease or suspected or known cardiac disease

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Translational development of MRI sequences
時間枠:on going

Possible comparison to other studies that subjects may have undergone. Descriptive MRI catalogue of multiple cardiovascular processes Follow-up of outcomes subsequent to the MRI scan in select subject groups Follow-up of changes in diagnosis following the MRI scan in select subject groups

on going
Technical development of MRI sequences
時間枠:on going

Possible assessments include structure depictions, heart chamber volumes, blood flow velocity, image quality scores, pixelwise and segmental summary scores of parametric maps in the heart. Anatomical imaging may be assessed for non- cardiac applications. Contrast- to-noise, and signal-to-noise measurements may be performed. For novel sequences, comparisons to standard product sequences may be performed.

on going
Evaluating the correlation
時間枠:on going

Measurements of cardiac chamber size and function, vascular reactivity and perfusion are among the parameters that may be followed with comparison to standard biomarkers of disease and clinical manifestations of disease. Neurologic vascular reactivity, blood volume, resting state connectivity, BOLD signal changes may be compared among healthy subjects, asymptomatic subjects with risk factors, and subjects with disease.

on going
Assesment of Gad deposition in the brain
時間枠:on going

Assessment of non-contrast MRI findings that are consistent with gadolinium deposition.

on going

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:W. Patricia Bandettini, M.D.、National Heart, Lung, and Blood Institute (NHLBI)

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2018年7月12日

一次修了 (推定)

2028年4月1日

研究の完了 (推定)

2028年4月1日

試験登録日

最初に提出

2018年7月3日

QC基準を満たした最初の提出物

2018年7月7日

最初の投稿 (実際)

2018年7月10日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月5日

QC基準を満たした最後の更新が送信されました

2026年10月2日

最終確認日

2026年9月29日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

IPD プランの説明

The study team will make a decision on this matter.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する